Literature DB >> 26041084

Metabolic patterns in prion diseases: an FDG PET voxel-based analysis.

Elena Prieto1, Inés Domínguez-Prado, Mario Riverol, Sara Ortega-Cubero, María Jesús Ribelles, María Rosario Luquin, Purificación de Castro, Javier Arbizu.   

Abstract

PURPOSE: Clinical diagnosis of human prion diseases can be challenging since symptoms are common to other disorders associated with rapidly progressive dementia. In this context, (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) might be a useful complementary tool. The aim of this study was to determine the metabolic pattern in human prion diseases, particularly sporadic Creutzfeldt-Jakob disease (sCJD), the new variant of Creutzfeldt-Jakob disease (vCJD) and fatal familial insomnia (FFI).
METHODS: We retrospectively studied 17 patients with a definitive, probable or possible prion disease who underwent FDG PET in our institution. Of these patients, 12 were diagnosed as sCJD (9 definitive, 2 probable and 1 possible), 1 was diagnosed as definitive vCJD and 4 were diagnosed as definitive FFI. The hypometabolic pattern of each individual and comparisons across the groups of subjects (control subjects, sCJD and FFI) were evaluated using a voxel-based analysis.
RESULTS: The sCJD group exhibited a pattern of hypometabolism that affected both subcortical (bilateral caudate, thalamus) and cortical (frontal cortex) structures, while the FFI group only presented a slight hypometabolism in the thalamus. Individual analysis demonstrated a considerable variability of metabolic patterns among patients, with the thalamus and basal ganglia the most frequently affected areas, combined in some cases with frontal and temporal hypometabolism.
CONCLUSION: Patients with a prion disease exhibit a characteristic pattern of brain metabolism presentation in FDG PET imaging. Consequently, in patients with rapidly progressive cognitive impairment, the detection of these patterns in the FDG PET study could orient the diagnosis to a prion disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26041084     DOI: 10.1007/s00259-015-3090-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  21 in total

1.  Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies.

Authors:  Pietro Cortelli; Daniela Perani; Pasquale Montagna; Roberto Gallassi; Paolo Tinuper; Federica Provini; Provini Federica; Patrizia Avoni; Franco Ferrillo; Davide Anchisi; Rosa Maria Moresco; Ferruccio Fazio; Piero Parchi; Agostino Baruzzi; Elio Lugaresi; Pierluigi Gambetti
Journal:  Brain       Date:  2006-01-06       Impact factor: 13.501

2.  Glucose metabolism in sporadic Creutzfeldt-Jakob disease: a statistical parametric mapping analysis of (18) F-FDG PET.

Authors:  E-J Kim; S-S Cho; B-H Jeong; Y-S Kim; S W Seo; D L Na; M D Geschwind; Y Jeong
Journal:  Eur J Neurol       Date:  2011-11-04       Impact factor: 6.089

3.  Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.

Authors:  S Minoshima; N L Foster; A A Sima; K A Frey; R L Albin; D E Kuhl
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

Review 4.  Imaging of prion diseases.

Authors:  Laurent Letourneau-Guillon; Ryan Wada; Walter Kucharczyk
Journal:  J Magn Reson Imaging       Date:  2012-05       Impact factor: 4.813

Review 5.  Familial and sporadic fatal insomnia.

Authors:  Pasquale Montagna; Pierluigi Gambetti; Pietro Cortelli; Elio Lugaresi
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

6.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

7.  Glucose metabolism in nine patients with probable sporadic Creutzfeldt-Jakob disease: FDG-PET study using SPM and individual patient analysis.

Authors:  Dimitri Renard; Rik Vandenberghe; Laurent Collombier; Pierre-Olivier Kotzki; Jean-Pierre Pouget; Vincent Boudousq
Journal:  J Neurol       Date:  2013-09-26       Impact factor: 4.849

8.  11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

Authors:  V L Villemagne; C A McLean; K Reardon; A Boyd; V Lewis; G Klug; G Jones; D Baxendale; C L Masters; C C Rowe; S J Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-03-29       Impact factor: 10.154

9.  Comparison of diffusion-weighted MRI with 18F-fluorodeoxyglucose-positron emission tomography/CT and electroencephalography in sporadic Creutzfeldt-Jakob disease.

Authors:  Xiao-wei Xing; Jia-tang Zhang; Fei Zhu; Lin Ma; Da-yi Yin; Wei-quan Jia; Xu-sheng Huang; Chuan-qiang Pu; Sen-yang Lang; Sheng-yuan Yu
Journal:  J Clin Neurosci       Date:  2012-07-12       Impact factor: 1.961

10.  Chinese specific characteristics of sporadic Creutzfeldt-Jakob disease: a retrospective analysis of 57 cases.

Authors:  Wei Zhao; Jia-Tang Zhang; Xiao-Wei Xing; De-Hui Huang; Cheng-Lin Tian; Wei-Quan Jia; Xu-Sheng Huang; Wei-Ping Wu; Chuan-Qiang Pu; Sen-Yang Lang; Sheng-Yuan Yu
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more
  8 in total

1.  Amyloid- and FDG-PET in sporadic Creutzfeldt-Jakob disease: Correlation with pathological prion protein in neuropathology.

Authors:  Jordi A Matías-Guiu; Carmen Guerrero-Márquez; María Nieves Cabrera-Martín; Ulises Gómez-Pinedo; María Romeral; Diego Mayo; Jesús Porta-Etessam; Teresa Moreno-Ramos; José Luis Carreras; Jorge Matías-Guiu
Journal:  Prion       Date:  2017-05-16       Impact factor: 3.931

Review 2.  Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations.

Authors:  Franc Llorens; Juan-José Zarranz; Andre Fischer; Inga Zerr; Isidro Ferrer
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

3.  An In Vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease.

Authors:  Leonardo Iaccarino; Rosa Maria Moresco; Luca Presotto; Orso Bugiani; Sandro Iannaccone; Giorgio Giaccone; Fabrizio Tagliavini; Daniela Perani
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

4.  Combined findings of FDG-PET and arterial spin labeling in sporadic Creutzfeldt-Jakob disease.

Authors:  Junliang Yuan; Shuangkun Wang; Wenli Hu
Journal:  Prion       Date:  2018-10-09       Impact factor: 3.931

5.  Autoimmune Encephalitis versus Creutzfeldt-Jakob disease in a patient with typical Facio-brachial dystonic seizures: A case report with Diagnostic challenges.

Authors:  Vaibhav Seth; Suman Kushwaha; Ritu Verma; Priyankkumar Mukeshbhai Patel; R Kiran Gowda; Prateek Bapat
Journal:  Brain Behav Immun Health       Date:  2021-03-13

6.  18FDG PET-CT in sporadic Creutzfeldt-Jakob disease, correlated with MRI and histology.

Authors:  Nicholas C D Morley; Monika Hofer; Philip Wilkinson; Kevin M Bradley
Journal:  World J Nucl Med       Date:  2021-10-12

7.  Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions.

Authors:  Jing Zhang; Min Chu; ZiChen Tian; KeXin Xie; Yue Cui; Li Liu; JiaLi Meng; HaiHan Yan; Yang-Mingyue Ji; Zhuyi Jiang; Tian-Xinyu Xia; Dongxin Wang; Xin Wang; Ye Zhao; Hong Ye; Junjie Li; Lin Wang; Liyong Wu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-10-19       Impact factor: 10.154

8.  An in vivo 11C-PK PET study of microglia activation in Fatal Familial Insomnia.

Authors:  Leonardo Iaccarino; Luca Presotto; Valentino Bettinardi; Luigi Gianolli; Ignazio Roiter; Sabina Capellari; Piero Parchi; Pietro Cortelli; Daniela Perani
Journal:  Ann Clin Transl Neurol       Date:  2017-12-09       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.